A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid ...

For the purpose of clarity, the signaling pathways can be discussed in isolation. However, in reality there is considerable cross-talk between pathways, with parallel or upstream input from other ...

Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...

TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. This is an ASCO Meeting Abstract from the 2014 ASCO Annual ...